Unknown PHASE2 INTERVENTIONAL 2-arm NCT03271255

Apatinib Versus Bevacizumab in Second-line Therapy for Colorectal Cancer(ABST-C)

Apatinib Versus Bevacizumab in Combination With Second-line FOLFIRI in Patients With Metastatic Colorectal Cancer That Progressed During or After First-line Bevacizumab Plus an Oxaliplatin-based Regimen: A Randomised Phase 2 Trial

Sponsor: Shenzhen People's Hospital

Conditions Colorectal Neoplasms Digestive System Neoplasms Gastrointestinal Neoplasms Intestinal Neoplasms

Interventions Apatinib Mesylate Tablets Bevacizumab Injection

Updated 7 times since 2017 Last updated: Jan 20, 2019 Started: May 23, 2018 Primary completion: Sep 30, 2022 Completion: Dec 31, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Colorectal Neoplasms and Digestive System Neoplasms, this trial is ongoing. The trial is conducted by Shenzhen People's Hospital and has accumulated 7 data snapshots since 2018. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Feb 2023 — Jul 2024 [monthly]

Unknown Status PHASE2

Status: Recruiting → Unknown Status
Jan 2021 — Feb 2023 [monthly]

Recruiting PHASE2
Feb 2019 — Jan 2021 [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting

▶ Show 2 earlier versions

Jun 2018 — Feb 2019 [monthly]

Not Yet Recruiting PHASE2
Oct 2017 — Jun 2018 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Shenzhen People's Hospital

Data source: Shenzhen People's Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Shenzhen, China